Introduction
Compounds that interfere with the process of cell division have proven to be effective therapeutic agents in multiple types of cancer. A new generation of anti-mitotic drugs has recently entered clinical testing, including those targeting Polo-like kinase 1 (Plk1) (Tsykunova, et al., 2012; Schoffski, 2009) . Genetic screens in yeast and Drosophila had identified key regulators of mitosis, such as the founding member of the Polo-like kinase family (Fenton and Glover, 1993) . Since then, 5 mammalian homologs have been discovered, numbered Plk1 to Plk5, which exhibit largely non-redundant functions and are differently expressed, localized and regulated in cells (Zitouni, et al., 2014) . While Plk2, Plk3 and Plk4 have been implicated in G1-S phase transition and centriole duplication, human Plk5 encodes a truncated protein that lacks part of the kinase domain and is therefore kinaseactivity deficient (Strebhardt, 2010) . Plk1 is the best characterized member of the Polo-like kinase family and has been shown to control essential steps during mitosis (Petronczki, et al., 2008) . Plk1 mRNA and protein expression occurs in a cell cycle-dependent manner with peak levels in late G2 and M phase (Golsteyn, et al., 1994; Hamanaka, et al., 1995) . The catalytic activity and subcellular localization of Plk1 are tightly regulated during cell cycle progression (Golsteyn, et al., 1995) . The enzyme is located at centrosomes and kinetochores during early mitosis, and a fraction translocates to the midzone/midbody late in mitosis.
Consistent with its biological role, Plk1 is highly expressed in proliferating cells and therefore appears to be over-expressed in a broad spectrum of cancers, with high expression levels being correlated with poor prognosis in several cancer types (Takai, et al., 2005) . Taken together, these observations highlight Plk1 as an attractive molecular target for cancer nM, respectively, and shows somewhat lower potency on Plk3 (56 nM) (Rudolph, et al., 2009) but does not inhibit Plk4 (> 20 μM) (Supplemental Figure 1 ). Assays using a panel of more than 50 other kinases failed to identify any inhibitory activity at concentrations up to 10 μM, demonstrating that volasertib is highly selective for the Plk family. Volasertib perturbs centrosome maturation and separation and leads to the formation of a monopolar spindle, resulting in a temporary prometaphase arrest due to activation of the spindle assembly checkpoint. Prolonged arrest finally results in apoptosis. Although we cannot exclude that inhibition of other Plk family members contributes to the efficacy of volasertib, experiments using siRNA indicate that inhibition of Plk1 is sufficient to explain the anti-proliferative and pro-apoptotic activity of this compound (Liu and Erikson, 2003; Steegmaier, et al., 2007; Lenart, et al., 2007; Sumara, et al., 2004) . Volasertib has shown efficacy in multiple solid tumor xenograft models of human cancer at well-tolerated doses (Rudolph, et al., 2009) , and signs of efficacy have been observed in early clinical studies in patients with solid tumors (Janning and Fiedler, 2014 ). Here we report on the pharmacological profile of volasertib in multiple preclinical models of AML including established cell lines, bone marrow samples of AML patients in short-term culture and subcutaneous as well as disseminated in vivo models in immune-deficient mice. Considering the high intrinsic genetic instability and heterogeneity of AML, it is generally believed that combination regimens will be required to achieve the desired clinical efficacy. Here we have tested whether volasertib cooperates with established or emerging therapeutic agents when analyzed in these AML models. In the present study,
we were able to show in vivo efficacy of volasertib as a single agent but also in combination with chemotherapeutic agents such as cytarabine, decitabine, azacitidine or investigational targeted agents such as the FLT3 inhibitor quizartinib. (StemCell), 50 ng/ml IL-3 (StemCell), 40 ng/ml of IL-6 (Miltenyi Biotech), 200 ng/ml granulocyte macrophage colony-stimulating factor (Peprotech), 200 ng/ml granulocyte colony-stimulating factor (Peprotech), 4 U/ml erythropoietin (EPO, StemCell), 0.94 g/L human transferrin and 5x10 -5 mmol/L 2-mercaptoethanol (Sigma). To identify live leukemic cells, two antibodies that unequivocally identify the pathological cell population in the patient sample were selected in combination with Annexin-V. EC 50 values were extrapolated from the dose response curve fit. Studies were performed at Vivia Biotech, Madrid, Spain.
Western blot analysis
Protein extracts (15 µg) from volasertib or nocodazole treated MV-4-11 cells were separated by SDS-PAGE. Immunoblotting was carried out by TransBlot Turbo Transfer System (BioRad). Staining was performed with the corresponding antibodies recognizing phospho-Thr199 NPM, total NPM, phospho-Ser46 TCTP, total TCTP, -actin (Cell Signaling), phospho-Ser10 histone H3 (Millipore) and total histone H3 (Thermo Fisher Scientific). The ECL system (GE Healthcare) was used for detection.
FACS analysis
MV-4-11 cells were incubated for 24, 48 and 72 h with 0.1% DMSO or volasertib at various concentrations. To determine DNA content, cell suspensions were fixed in 80% ethanol, treated for 5 min with 0.25% Triton X-100 in PBS and incubated with 0.1% RNAse and 10 µg/ml propidium iodide (PI) in PBS for 20 min at RT. Cell-cycle profiles were determined by flow cytometry (FACSCanto TM , BD Biosciences). Reader using the AlphaScreen specs from PerkinElmer. IC 50 values were calculated using a 4 parametric logistic model.
PLK4 kinase assay
The assay was performed at Life Technologies using the LantaScreen® Eu kinase binding assay system. In brief, binding of an Alexa Fluor® conjugate or "tracer" to a kinase is detected by addition of a Eu-labeled anti-tag antibody. Binding of the tracer and antibody to a kinase results in a high degree of FRET, whereas displacement of the tracer with a kinase inhibitor results in loss of FRET. For the PLK4 kinase assay, tracer 236 at a tracer concentration of 1 nM was used. Routinely, test compounds are screened in 1% DMSO (final concentration), 10 point titrations with 3-fold serial compound dilutions were conducted using 20 µM as a start concentration. The incubation time was 1 h. Staurosporine is reported to interfere with PLK4 at an IC 50 of 1.82 nM and serves as a positive control for this assay.
Viability assays
1x10 5 cells/ well were plated in 96-well flat bottom microtiter plates and incubated overnight at 37 °C in a CO2 incubator. Test compound was added at various concentrations for 72 hours. After 6-hour incubation with Alamar Blue solution (Invitrogen) at 37°C, fluorescence was measured (Envision MultiModeReader, PerkinElmer) using an excitation wavelength of 531 nm and emission at 595 nm. Data analysis: Data were fitted by iterative calculation using a sigmoidal curve analysis program (Prism version 3.0, Graph Pad) with variable hill slope. EC 50 values were calculated. 3D assays in matrigel were performed as described (Li, et al., 2008) . 
Efficacy studies in mice

Results
Volasertib inhibits proliferation of AML cell lines and patient-derived AML blasts
To test the activity of volasertib in a broad range of preclinical models we initially selected a panel of 8 established AML cell lines representing a spectrum of genetic aberrations (Table 1) . Volasertib showed efficacy in 2D and 3D assays, respectively, using
Alamar Blue staining as a measure of viability with EC 50 values in the range of 16-170 nM in the 2D assay format and 19-40 nM in the 3D matrigel assay format (Table 1) . Moreover, bone marrow samples from 14 AML patients were also tested in 2D assays followed by flow cytometry using Annexin-V to detect live vs. apoptotic leukemic cells ( 
Volasertib mechanism of action
The AML cell line MV-4-11 was used to study the effect of volasertib on cell cycle progression. Propidium iodide staining and flow cytometry of cells treated with volasertib showed a time-and dose-dependent increase in the G2/M peak followed by an increase in the sub-G1 peak at 48 and 72 h, indicative of cell death ( Figure 1A-B) . Similar results were obtained in an independent study using Kasumi-1 cells (Supplemental Figure 2) . To discriminate between an arrest in G2 phase or M phase of the cell cycle, several markers were assessed by Western blot analysis ( Figure 1C ). Increased phosphorylation of histone H3 (Ser10) and nucleophosmin (NPM; Thr199) clearly demonstrates mitotic arrest of MV-4-11 cells treated with volasertib. In line with this, treatment with nocodazole, a microtubulestabilizing agent that arrests cells in mitosis, leads to a similar pattern of marker modulation.
However, increased levels of phospho-TCTP (translationally controlled tumor protein; Ser46), another marker of mitosis and a Plk1 substrate (Cucchi, et al., 2010) , were observed after treatment with nocodazole, while treatment with volasertib resulted in a decrease in
phospho-TCTP to undetectable levels within 1 h. These data indicate that volasertib arrests cells in early mitosis. In additional assays, live-cell imaging of MV-4-11 cells was performed over 36 h to measure cell density, and a caspase 3/7 live cell fluorescent stain was used to detect apoptotic cells ( Figure 1D ). The results confirm that volasertib inhibits proliferation and induces apoptosis.
To assess the phenotype of volasertib-treated cells in more detail, we performed long-term live-cell imaging experiments. As AML cells growing in suspension are not suitable for this assay, we used HeLa cells engineered to express a fusion protein of histone 2b with the fluorescent protein mCherry as a chromatin marker. Volasertib reduced the rate of entry into prometaphase in these cells and strongly interfered with mitotic progression (Figure 2 ).
In contrast to untreated control cells, most cells that entered mitosis in the presence of volasertib did not progress to anaphase, but remained in a prolonged prometaphase followed by cell death or mitotic exit without chromosome segregation. A summary statistics of mitotic entry rates ( Figure 2D ) and individual cell fates ( Figure 2E -G) shows that inhibition of mitotic entry and the incidence of mitotic failures correlates with increasing concentrations of volasertib. Hence, volasertib inhibits proliferation by reducing the rate of prometaphase entry and by perturbing mitosis in early prometaphase.
Recently published data suggest that volasertib binds to the first bromodomain of BRD4, a member of the bromodomain and extra-terminal (BET) family of proteins that acts as a reader of epigenetic marks (Ciceri, et al., 2014) . To investigate the pharmacological relevance of this interaction, we performed assays measuring the displacement of an acetylated histone H4-derived peptide from the bromodomains 1 or 2 of BRD4 ( Figure 3 A-B).
IC 50 values for volasertib in these two assays were 300 and 770 nM, respectively, confirming Figure 4A ). All dose levels were well tolerated as neither body weight loss nor adverse signs were observed ( Figure 4B ). Of note, 40 mg/kg once weekly had previously been defined as the MTD.
While subcutaneous xenograft models are widely used for compound profiling, we also attempted to assess the efficacy of volasertib in AML models which more closely reflect the clinical situation. To this end, 10 7 MOLM-13 or MV-4-11 cells, stably transfected with a luciferase-expression vector to allow assessment of tumor load by bioluminescence imaging, were injected into the tail vein of CIEA-NOG mice. Treatment with volasertib at 20 mg/kg or
treated at 40 mg/kg, the survival endpoint was not reached (>61 days, >85% increase) (data not shown).
Volasertib in combination with established and investigational therapeutic agents
The anti-metabolite cytarabine is a standard-of-care agent in the treatment of AML patients. A combination of volasertib with cytarabine was therefore tested in a patient-derived subcutaneous xenograft model, AML-6252. Tumor-bearing SCID-beige mice were treated i.v. Figure 5C ). Of note, even though single-agent azacitidine resulted in a median body weight loss up to 8%, tolerability did not deteriorate further when volasertib was added to this treatment regimen ( Figure 5D ).
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The potential of FLT3 inhibition as a therapeutic option for AML patients is currently being evaluated in clinical studies. We tested the combination of volasertib with the FLT3 inhibitor quizartinib in the subcutaneous MV-4-11 xenograft model characterized by an FLT3 internal tandem repeat mutation ( Figure 5E -F). Animals were treated for 2 weeks either with 20 mg/kg volasertib i.v. once weekly, with a daily oral dose of quizartinib (5 or 10 mg/kg) or with a combination of these agents. At the end of the treatment period, efficacy of singleagent quizartinib was comparable to that observed with the drug combination. However, during a post-treatment observation period, tumors in the quizartinib groups started to regrow 45-60 days after termination of treatment, whereas combination with volasertib resulted in long-term efficacy without evidence for tumor regrowth until the last day of the study, 72 days after termination of treatment.
Discussion
In recent years, advances in our knowledge of the regulation of cell division have resulted in the identification of several potential mitosis-specific targets for therapeutic intervention, including Plk1. Plk1 is expressed in dividing cells in a cell cycle-dependent manner, with low expression during the G0/G1 phase, a rise in S phase and peak levels in M phase (Hamanaka, et al., 1995) . Plk1 has previously been found to be aberrantly expressed in AML cells compared with normal bone marrow mononuclear cells (Renner, et al., 2009; Ikezoe, et al., 2009) , and has often been correlated with poor prognosis, disease stage, histologic grade, metastatic potential and survival (Takai, et al., 2005 we demonstrate that treatment of AML cells with volasertib leads to potent and selective inhibition of Plk1, as specified by inhibition of p-TCTP, a Plk1 substrate and subsequent mitotic arrest followed by a strong induction of apoptosis. In our analysis of AML cell lines as well as patient samples in viability assays, the large majority of those were highly sensitive to volasertib, irrespective of karyotype and mutational status.
A recent publication has claimed that volasertib may have an additional inhibitory activity and could be a dual kinase-bromodomain inhibitor based on data showing that volasertib binds to the bromodomain of BRD4 (Ciceri, et al., 2014) . In AML, the gene encoding BRD4 was identified by an epigenetically focused systematic in vivo RNAi screen as highly essential for promoting proliferation and blocking differentiation (Zuber, et al., 2011) .
When using a BRD4 inhibitory compound, anti-leukemic effects across genomic AML subtypes were precisely recapitulated and found to largely depend on blocking the oncogenic transcription factor MYC (Zuber, et al., 2011 Considering the high intrinsic genetic instability and heterogeneity of AML cells, it is generally believed that combination regimens will be required to achieve the desired clinical efficacy. Therefore, it was of considerable interest to learn whether volasertib would cooperate with established or emerging therapeutic agents when analyzed in AML models. In the present study, we were able to show in vivo efficacy of volasertib as a single agent but also in combination with chemotherapeutic agents such as cytarabine, decitabine, azacitidine or investigational targeted agents such as the FLT3 inhibitor quizartinib. Remarkably, in all combinations, efficacy of standard agents is improved and this is not offset by toxicity.
Further studies will be required to elucidate the detailed molecular mechanisms underlying these combinatorial effects.
Volasertib is the first Plk inhibitor that has advanced to late-stage clinical development.
Early clinical studies in patients with solid tumors had indicated that the compound has therapeutic potential and is well tolerated (Gjertsen and Schoffski, 2014), with mainly hematological toxicities and the notable absence of neuropathies, and thus may be particularly beneficial for patients unable to tolerate aggressive chemotherapy. Importantly, recent clinical data in AML patients showed that volasertib combined with low-dose cytarabine (LDAC) was associated with higher response rates and improved event-free survival than LDAC alone (Dohner, et al., 2014) . On this basis, volasertib in combination with low-dose cytarabine (LDAC) is currently being evaluated in a Phase III clinical study in 
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